Zafgen, Inc. (NASDAQ:ZFGN) Files An 8-K Regulation FD DisclosureItem 7.01
On June23, 2018, Zafgen, Inc. (the “Company”) issued a press release announcing new data from its ongoing Phase 2 Proof-of-Concept Trial of ZGN-1061 for Patients with Difficult-to-Control Type 2 Diabetes. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K and is incorporated herein by reference.
In addition, on Monday June25, 2018, the Company will host an investor conference call to discuss ZGN-1061 Phase 2 data results and clinical development plans as well as two nonclinical studies for ZGN-1061, which will be presented as late-breaker abstracts at the American Diabetes Association 78th Scientific Sessions in Orlando, Florida. A copy of the press release issued as a reminder for the call is being furnished as Exhibit 99.2 to this Report on Form 8-K and is incorporated by reference herein.
The information in this Report on Form 8-K and Exhibits 99.1 and 99.2 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
|Item 7.01||Financial Statements and Exhibits.|
|99.1||Press release issued by Zafgen, Inc. on June23, 2018, furnished herewith.|
|99.2||Press release issued by Zafgen, Inc. on June25, 2018, furnished herewith.|
ZAFGEN, INC. ExhibitEX-99.1 2 d466524dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes Trial met all primary objectives,…To view the full exhibit click
About Zafgen, Inc. (NASDAQ:ZFGN)
Zafgen, Inc. is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity. Beloranib is in Phase III stage of development for PWS. It is also developing ZGN-839, a liver-targeted methionine aminopeptidase 2 (MetAP2) inhibitor, for the treatment of nonalcoholic steatohepatitis (NASH) and abdominal obesity, as well as other second-generation MetAP2 inhibitors for the treatment of severe obesity. It is also evaluating additional MetAP2 inhibitors beyond Beloranib as a development candidate for the treatment of severe obesity in the general population.